ID   RIOK1_HUMAN             Reviewed;         568 AA.
AC   Q9BRS2; B2RB28; Q8NDC8; Q96NV9;
DT   07-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2004, sequence version 2.
DT   12-OCT-2022, entry version 165.
DE   RecName: Full=Serine/threonine-protein kinase RIO1;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:22072790};
DE            EC=3.6.3.-;
DE   AltName: Full=RIO kinase 1;
GN   Name=RIOK1 {ECO:0000312|HGNC:HGNC:18656}; Synonyms=RIO1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 44-568.
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   PROTEIN SEQUENCE OF 156-165; 191-205; 212-218; 380-401 AND 482-493, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma, and Lung carcinoma;
RA   Bienvenut W.V., Vousden K.H., Lukashchuk N., Calvo F., Kolch W.;
RL   Submitted (MAR-2008) to UniProtKB.
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21 AND SER-22, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   SUBUNIT, SUBCELLULAR LOCATION, INTERACTION WITH PRMT5 AND NCL,
RP   IDENTIFICATION IN A COMPLEX WITH PRTM5; WDR77 AND RIOK1, IDENTIFICATION BY
RP   MASS SPECTROMETRY, AND FUNCTION.
RX   PubMed=21081503; DOI=10.1074/jbc.m110.148486;
RA   Guderian G., Peter C., Wiesner J., Sickmann A., Schulze-Osthoff K.,
RA   Fischer U., Grimmler M.;
RT   "RioK1, a new interactor of protein arginine methyltransferase 5 (PRMT5),
RT   competes with pICln for binding and modulates PRMT5 complex composition and
RT   substrate specificity.";
RL   J. Biol. Chem. 286:1976-1986(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [13]
RP   FUNCTION, INTERACTION WITH PRMT5 AND WDR77, SUBUNIT, ACTIVE SITE, AND
RP   MUTAGENESIS OF ASP-324.
RX   PubMed=22072790; DOI=10.1091/mbc.e11-07-0639;
RA   Widmann B., Wandrey F., Badertscher L., Wyler E., Pfannstiel J., Zemp I.,
RA   Kutay U.;
RT   "The kinase activity of human Rio1 is required for final steps of
RT   cytoplasmic maturation of 40S subunits.";
RL   Mol. Biol. Cell 23:22-35(2012).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 143-494 IN COMPLEX WITH ADP, AND
RP   COFACTOR.
RX   PubMed=24948609; DOI=10.1093/nar/gku542;
RA   Ferreira-Cerca S., Kiburu I., Thomson E., LaRonde N., Hurt E.;
RT   "Dominant Rio1 kinase/ATPase catalytic mutant induces trapping of late pre-
RT   40S biogenesis factors in 80S-like ribosomes.";
RL   Nucleic Acids Res. 42:8635-8647(2014).
CC   -!- FUNCTION: Involved in the final steps of cytoplasmic maturation of the
CC       40S ribosomal subunit. Involved in processing of 18S-E pre-rRNA to the
CC       mature 18S rRNA. Required for the recycling of NOB1 and PNO1 from the
CC       late 40S precursor (PubMed:22072790). The association with the very
CC       late 40S subunit intermediate may involve a translation-like checkpoint
CC       point cycle preceeding the binding to the 60S ribosomal subunit (By
CC       similarity). Despite the protein kinase domain is proposed to act
CC       predominantly as an ATPase (By similarity). The catalytic activity
CC       regulates its dynamic association with the 40S subunit (By similarity).
CC       In addition to its role in ribosomal biogenesis acts as an adapter
CC       protein by recruiting NCL/nucleolin the to PRMT5 complex for its
CC       symmetrical methylation (PubMed:21081503).
CC       {ECO:0000250|UniProtKB:G0S3J5, ECO:0000250|UniProtKB:Q12196,
CC       ECO:0000269|PubMed:21081503, ECO:0000269|PubMed:22072790}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:22072790};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:22072790};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:24948609, ECO:0000305};
CC   -!- SUBUNIT: Associates with the precursor of the 40S ribosome subunit.
CC       Interacts (via its N-terminus) with PRMT5 (via its N-terminus)
CC       (PubMed:22072790, PubMed:21081503). Interacts with WDR77
CC       (PubMed:22072790). Found in a PRMT5 complex composed of PRMT5, WDR77
CC       and RIOK1 (PubMed:21081503). Interacts (via its C-terminus) with NCL;
CC       this interaction targets NCL for PRTM5 methylation (PubMed:21081503).
CC       {ECO:0000269|PubMed:21081503, ECO:0000269|PubMed:22072790}.
CC   -!- INTERACTION:
CC       Q9BRS2; O14744: PRMT5; NbExp=5; IntAct=EBI-7307838, EBI-351098;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:21081503}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. RIO-type Ser/Thr
CC       kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK054568; BAB70761.1; -; mRNA.
DR   EMBL; AK314467; BAG37075.1; -; mRNA.
DR   EMBL; CH471087; EAW55210.1; -; Genomic_DNA.
DR   EMBL; BC006104; AAH06104.2; -; mRNA.
DR   EMBL; AL834277; CAD38952.1; -; mRNA.
DR   CCDS; CCDS4500.1; -.
DR   RefSeq; NP_113668.2; NM_031480.2.
DR   PDB; 4OTP; X-ray; 2.70 A; A=143-494.
DR   PDB; 6G5I; EM; 3.50 A; z=1-568.
DR   PDB; 6V0N; X-ray; 2.11 A; C=11-23.
DR   PDB; 6ZV6; EM; 2.90 A; h=1-568.
DR   PDB; 6ZXD; EM; 3.20 A; z=1-568.
DR   PDB; 6ZXE; EM; 3.00 A; z=1-568.
DR   PDB; 6ZXF; EM; 3.70 A; z=1-568.
DR   PDB; 6ZXG; EM; 2.60 A; z=1-568.
DR   PDB; 6ZXH; EM; 2.70 A; z=1-568.
DR   PDB; 7BOC; X-ray; 2.55 A; B=9-23.
DR   PDBsum; 4OTP; -.
DR   PDBsum; 6G5I; -.
DR   PDBsum; 6V0N; -.
DR   PDBsum; 6ZV6; -.
DR   PDBsum; 6ZXD; -.
DR   PDBsum; 6ZXE; -.
DR   PDBsum; 6ZXF; -.
DR   PDBsum; 6ZXG; -.
DR   PDBsum; 6ZXH; -.
DR   PDBsum; 7BOC; -.
DR   AlphaFoldDB; Q9BRS2; -.
DR   SMR; Q9BRS2; -.
DR   BioGRID; 123743; 532.
DR   IntAct; Q9BRS2; 42.
DR   MINT; Q9BRS2; -.
DR   STRING; 9606.ENSP00000369162; -.
DR   BindingDB; Q9BRS2; -.
DR   ChEMBL; CHEMBL5975; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9BRS2; -.
DR   iPTMnet; Q9BRS2; -.
DR   MetOSite; Q9BRS2; -.
DR   PhosphoSitePlus; Q9BRS2; -.
DR   BioMuta; RIOK1; -.
DR   DMDM; 56404949; -.
DR   EPD; Q9BRS2; -.
DR   jPOST; Q9BRS2; -.
DR   MassIVE; Q9BRS2; -.
DR   MaxQB; Q9BRS2; -.
DR   PaxDb; Q9BRS2; -.
DR   PeptideAtlas; Q9BRS2; -.
DR   PRIDE; Q9BRS2; -.
DR   ProteomicsDB; 78823; -.
DR   Antibodypedia; 24663; 207 antibodies from 29 providers.
DR   DNASU; 83732; -.
DR   Ensembl; ENST00000379834.7; ENSP00000369162.2; ENSG00000124784.9.
DR   GeneID; 83732; -.
DR   KEGG; hsa:83732; -.
DR   MANE-Select; ENST00000379834.7; ENSP00000369162.2; NM_031480.3; NP_113668.2.
DR   UCSC; uc003mxn.4; human.
DR   CTD; 83732; -.
DR   DisGeNET; 83732; -.
DR   GeneCards; RIOK1; -.
DR   HGNC; HGNC:18656; RIOK1.
DR   HPA; ENSG00000124784; Low tissue specificity.
DR   MIM; 617753; gene.
DR   neXtProt; NX_Q9BRS2; -.
DR   OpenTargets; ENSG00000124784; -.
DR   PharmGKB; PA134928236; -.
DR   VEuPathDB; HostDB:ENSG00000124784; -.
DR   eggNOG; KOG2270; Eukaryota.
DR   GeneTree; ENSGT00940000157075; -.
DR   HOGENOM; CLU_018693_4_3_1; -.
DR   InParanoid; Q9BRS2; -.
DR   OMA; QEINGCI; -.
DR   OrthoDB; 1238900at2759; -.
DR   PhylomeDB; Q9BRS2; -.
DR   TreeFam; TF105831; -.
DR   PathwayCommons; Q9BRS2; -.
DR   Reactome; R-HSA-6791226; Major pathway of rRNA processing in the nucleolus and cytosol.
DR   SignaLink; Q9BRS2; -.
DR   BioGRID-ORCS; 83732; 778 hits in 1114 CRISPR screens.
DR   ChiTaRS; RIOK1; human.
DR   GenomeRNAi; 83732; -.
DR   Pharos; Q9BRS2; Tchem.
DR   PRO; PR:Q9BRS2; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q9BRS2; protein.
DR   Bgee; ENSG00000124784; Expressed in epithelial cell of pancreas and 164 other tissues.
DR   ExpressionAtlas; Q9BRS2; baseline and differential.
DR   Genevisible; Q9BRS2; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0034708; C:methyltransferase complex; IMP:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0030688; C:preribosome, small subunit precursor; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0030490; P:maturation of SSU-rRNA; IMP:UniProtKB.
DR   GO; GO:0016310; P:phosphorylation; IEA:UniProtKB-KW.
DR   GO; GO:2000234; P:positive regulation of rRNA processing; IMP:UniProtKB.
DR   GO; GO:0042274; P:ribosomal small subunit biogenesis; IMP:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000687; RIO_kinase.
DR   InterPro; IPR018935; RIO_kinase_CS.
DR   InterPro; IPR017407; Ser/Thr_kinase_Rio1.
DR   PIRSF; PIRSF038147; Ser/Thr_PK_RIO1; 1.
DR   SMART; SM00090; RIO; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01245; RIO1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cytoplasm; Direct protein sequencing; Hydrolase;
KW   Kinase; Magnesium; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Ribosome biogenesis; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN           1..568
FT                   /note="Serine/threonine-protein kinase RIO1"
FT                   /id="PRO_0000213526"
FT   DOMAIN          180..479
FT                   /note="Protein kinase"
FT   REGION          14..70
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          83..109
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          490..568
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        20..42
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        47..70
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        87..107
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        510..547
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        548..568
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        324
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000269|PubMed:22072790,
FT                   ECO:0000305|PubMed:24948609"
FT   ACT_SITE        341
FT                   /note="4-aspartylphosphate intermediate"
FT                   /evidence="ECO:0000269|PubMed:24948609,
FT                   ECO:0007744|PDB:4OTP"
FT   BINDING         208
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:24948609,
FT                   ECO:0007744|PDB:4OTP"
FT   BINDING         278
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:24948609,
FT                   ECO:0007744|PDB:4OTP"
FT   BINDING         280
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:24948609,
FT                   ECO:0007744|PDB:4OTP"
FT   BINDING         329
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000269|PubMed:24948609,
FT                   ECO:0007744|PDB:4OTP"
FT   BINDING         341
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000269|PubMed:24948609,
FT                   ECO:0007744|PDB:4OTP"
FT   MOD_RES         21
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         22
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   VARIANT         375
FT                   /note="V -> I (in dbSNP:rs56067778)"
FT                   /id="VAR_061777"
FT   MUTAGEN         324
FT                   /note="D->A: Abolishes autophosphorylation activity;
FT                   enhances association with pre-40S ribosomal subunits;
FT                   inhibits processing of 18S-E pre-rRNA to the mature 18S
FT                   rRNA."
FT                   /evidence="ECO:0000269|PubMed:22072790"
FT   TURN            13..16
FT                   /evidence="ECO:0007829|PDB:6V0N"
FT   STRAND          109..111
FT                   /evidence="ECO:0007829|PDB:6ZXD"
FT   HELIX           112..116
FT                   /evidence="ECO:0007829|PDB:6ZXD"
FT   HELIX           131..144
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   HELIX           152..155
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   STRAND          158..161
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   HELIX           164..175
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   STRAND          180..188
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   STRAND          190..198
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   STRAND          200..202
FT                   /evidence="ECO:0007829|PDB:6ZXE"
FT   STRAND          204..210
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   STRAND          223..226
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   HELIX           228..230
FT                   /evidence="ECO:0007829|PDB:6ZXH"
FT   STRAND          231..233
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   HELIX           239..259
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   STRAND          267..271
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   STRAND          274..278
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   STRAND          281..284
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   HELIX           290..292
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   HELIX           297..316
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   STRAND          329..333
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   STRAND          336..339
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   STRAND          346..350
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   HELIX           353..370
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   HELIX           378..386
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   STRAND          392..394
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   HELIX           395..407
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   HELIX           413..426
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   HELIX           439..451
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   HELIX           532..547
FT                   /evidence="ECO:0007829|PDB:6ZXG"
FT   HELIX           552..558
FT                   /evidence="ECO:0007829|PDB:6ZXG"
SQ   SEQUENCE   568 AA;  65583 MW;  5730BFC3798F5190 CRC64;
     MDYRRLLMSR VVPGQFDDAD SSDSENRDLK TVKEKDDILF EDLQDNVNEN GEGEIEDEEE
     EGYDDDDDDW DWDEGVGKLA KGYVWNGGSN PQANRQTSDS SSAKMSTPAD KVLRKFENKI
     NLDKLNVTDS VINKVTEKSR QKEADMYRIK DKADRATVEQ VLDPRTRMIL FKMLTRGIIT
     EINGCISTGK EANVYHASTA NGESRAIKIY KTSILVFKDR DKYVSGEFRF RHGYCKGNPR
     KMVKTWAEKE MRNLIRLNTA EIPCPEPIML RSHVLVMSFI GKDDMPAPLL KNVQLSESKA
     RELYLQVIQY MRRMYQDARL VHADLSEFNM LYHGGGVYII DVSQSVEHDH PHALEFLRKD
     CANVNDFFMR HSVAVMTVRE LFEFVTDPSI THENMDAYLS KAMEIASQRT KEERSSQDHV
     DEEVFKRAYI PRTLNEVKNY ERDMDIIMKL KEEDMAMNAQ QDNILYQTVT GLKKDLSGVQ
     KVPALLENQV EERTCSDSED IGSSECSDTD SEEQGDHARP KKHTTDPDID KKERKKMVKE
     AQREKRKNKI PKHVKKRKEK TAKTKKGK
//
